Mraz Amerine & Associates Inc. cut its stake in Novartis AG (NYSE:NVS – Free Report) by 27.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,592 shares of the company’s stock after selling 1,706 shares during the period. Mraz Amerine & Associates Inc.’s holdings in Novartis were worth $528,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of NVS. Raymond James & Associates lifted its position in Novartis by 1.3% during the second quarter. Raymond James & Associates now owns 536,607 shares of the company’s stock worth $57,127,000 after purchasing an additional 6,767 shares during the period. Manning & Napier Advisors LLC acquired a new position in shares of Novartis during the second quarter worth $15,044,000. O Shaughnessy Asset Management LLC lifted its stake in shares of Novartis by 6.5% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 180,764 shares of the company’s stock valued at $17,485,000 after acquiring an additional 11,080 shares during the last quarter. Integral Health Asset Management LLC boosted its holdings in shares of Novartis by 33.3% during the 2nd quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $31,938,000 after acquiring an additional 75,000 shares in the last quarter. Finally, FORA Capital LLC bought a new stake in Novartis during the 1st quarter worth $2,968,000. 13.12% of the stock is currently owned by institutional investors.
Novartis Trading Down 0.8 %
NYSE NVS opened at $113.16 on Friday. Novartis AG has a one year low of $92.19 and a one year high of $120.92. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72. The business has a 50 day simple moving average of $116.44 and a 200 day simple moving average of $108.39. The stock has a market capitalization of $231.30 billion, a P/E ratio of 15.27, a P/E/G ratio of 1.66 and a beta of 0.57.
Analyst Ratings Changes
View Our Latest Analysis on Novartis
Novartis Company Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Articles
- Five stocks we like better than Novartis
- How to Use Stock Screeners to Find Stocks
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- The Significance of Brokerage Rankings in Stock Selection
- The Downtrend in UPS Stock Isn’t Over Yet
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Maximize Portfolio Income with These 3 Dividend ETFs
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.